PropThink: PTIE Down on Disappointing Pfizer Commentary and Pushback; Stock Could Trade Lower

[ACN Newswire] – By David MoskowitzShares of Pain Therapeutics (NASDAQ:PTIE) are off 25% as partner Pfizer (NYSE:PFE) noted Thursday on its earnings call that Remoxy, PTIE’s lead product, is a challenging asset … more

View todays social media effects on PTIE

View the latest stocks trending across Twitter. Click to view dashboard